US Corporate Board Director Changes SEC Filings — June 05, 2026

05-06-2026

On June 4, 2026, Jordan Krugman notified the Invesco CurrencyShares British Pound Sterling Trust of his resignation from all positions at the Sponsor (Invesco Specialized Products, LLC) and its affiliates, including his role on the Board of Managers, effective August 3, 2026. The Sponsor is considering a replacement. No financial metrics or performance data are included in this filing.

• · Resignation effective date: August 3, 2026.
• · The Sponsor is currently considering Mr. Krugman's replacement.

05-06-2026

Woodward, Inc. announced the retirement of Terence J. Voskuil, Executive Vice President, Chief Technology Officer, Aerospace, effective October 2, 2026. Mr. Voskuil will continue in his current role until the effective date. No successor or interim replacement has been named in the filing.

• · The retirement is effective October 2, 2026.
• · Mr. Voskuil will continue serving in his current role until the effective date.
• · No successor or interim replacement has been announced in this filing.

05-06-2026

Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC and affiliates, including his role as a member of the Board of Managers, effective August 3, 2026. The Sponsor is considering his replacement. No financial impact is disclosed.

• · Resignation effective date: August 3, 2026
• · Notice given on June 4, 2026
• · Sponsor is currently considering replacement

05-06-2026

On June 4, 2026, Jordan Krugman resigned from all positions at Invesco Capital Management LLC (the Managing Owner) and its affiliates, including his role on the Board of Managers, effective August 3, 2026. The Managing Owner is currently considering his replacement. No financial impact or performance data is provided in this filing.

• · Resignation effective date: close of business on August 3, 2026.
• · The Managing Owner is currently considering Mr. Krugman's replacement.

05-06-2026

Invesco Galaxy Ethereum ETF (QETH) disclosed that Jordan Krugman resigned from all positions at the Sponsor, Invesco Capital Management LLC, effective August 3, 2026. The Sponsor is considering a replacement.

• · Resignation effective date: close of business on August 3, 2026.
• · ETF trades on Cboe BZX Exchange under symbol QETH.

05-06-2026

Seadrill Ltd held its 2026 Annual General Meeting on June 3, 2026, where shareholders approved all proposals, including the re-election of directors, appointment of PricewaterhouseCoopers LLP as auditor, director remuneration, an advisory vote on executive compensation, and Amendment No. 1 to the 2022 Management Incentive Plan. While most director nominees received strong support (over 95% of votes cast), Andrew Schultz received significant opposition with 11,963,111 votes against (approximately 27% of votes cast), and Jan Kjærvik also faced notable dissent with 4,745,978 against (roughly 11% against), indicating mixed shareholder sentiment on certain board members.

• · Proposal 3 (auditor appointment) was the most strongly supported, with 47,223,781 for vs only 79,918 against, and zero broker non-votes.
• · Proposal 2: Andrew Schultz received the highest opposition among director nominees: 11,963,111 against (27% of votes cast, excluding broker non-votes).
• · Jan Kjærvik also faced notable opposition: 4,745,978 against (10.9% of votes cast, excluding broker non-votes).
• · All other director nominees received over 98% approval among votes cast (excluding broker non-votes).
• · Proposal 6 (Incentive Plan amendment) was approved with 41,146,428 for and 2,201,541 against.
• · Proposal 5 (say-on-pay) passed with 41,033,521 for and 2,310,244 against — roughly 95% approval.
• · The board size will remain at up to 9 directors, as approved in Proposal 1.
• · The Meeting was held on June 3, 2026; results were reported on June 5, 2026.
• · PricewaterhouseCoopers LLP was appointed as independent auditor for FY2026.

05-06-2026

On June 3, 2026, DBV Technologies' Board approved the 2026 Performance Share Unit Plan and granted 4,060,000 PSUs to CEO Daniel Tassé, with vesting tied to FDA approval of Viaskin Peanut BLA for two age groups. The PSUs are split into 2,900,000 units for first FDA approval and 1,160,000 for a second approval, with a vesting deadline of July 1, 2028. While the grant aligns CEO incentives with key regulatory milestones, the plan carries significant risk as PSUs are forfeited if FDA approvals are not achieved by the deadline, and no financial metrics or current revenue are mentioned.

• · PSU vesting deadline is July 1, 2028; unvested PSUs are automatically cancelled and forfeited without compensation.
• · Vested shares will be delivered in four equal installments of 25% on July 1, 2028, January 1, 2029, July 1, 2029, and January 1, 2030.
• · Continued employment condition requires Mr. Tassé to remain CEO or employed by the company continuously from grant date through vesting date, with exceptions for death, disability, qualifying retirement, or termination without cause/for good reason.
• · Upon a Change in Control, all performance conditions are deemed achieved, but the continued employment condition and delivery schedule still apply.
• · If CEO is a specified employee under Section 409A, payments due upon separation from service are deferred for six months and one day.
• · Board may substitute cash payment for vested shares if CEO is not a French tax resident at delivery.

05-06-2026

On June 1, 2026, Longeveron Inc. CFO Lisa Locklear notified the company of her resignation, effective July 10, 2026, to pursue board opportunities and other interests. The company plans to elevate current controller Marie Washburn to the CFO role pending final contract. Locklear's departure is not due to any disagreement with the company's operations, policies, or practices.

• · CFO resignation effective July 10, 2026.
• · Controller Marie Washburn is anticipated to be elevated to CFO upon Locklear's departure, pending final contract.
• · Locklear's resignation was not due to any disagreement with the company.

05-06-2026

Assembly Biosciences, Inc. held its Annual Meeting on June 4, 2026, where stockholders approved all five proposals, including the election of nine director nominees, the ratification of Ernst & Young LLP as independent auditor, and the approval of amendments to the 2018 Stock Incentive Plan and Employee Stock Purchase Plan. The amendments increase the share reserve for the 2018 Plan from 1,478,333 to 2,678,333 shares and for the ESPP from 225,000 to 515,000 shares. All director nominees received strong support with votes for ranging from 11,274,020 to 11,312,521, while the advisory vote on executive compensation passed with 11,293,061 votes for and only 5,401 against.

• · The ratification of Ernst & Young LLP as independent auditor received 12,382,746 votes for, 2,943 against, and 175 abstain, with no broker non-votes.
• · The advisory vote on executive compensation passed with 11,293,061 votes for, 5,401 against, and 18,379 abstain.
• · Amendment No. 3 to the 2018 Plan was approved with 11,290,805 votes for, 24,242 against, and 1,794 abstain.
• · ESPP Amendment No. 2 was approved with 11,305,253 votes for, 9,343 against, and 2,245 abstain.
• · All director nominees received over 11.27 million votes for, with the lowest being John G. McHutchison at 11,274,020 votes for.

05-06-2026

Bionano Genomics, Inc. (BNGO) announced the resignation of Dr. Alka Chaubey as Chief Medical Officer, effective July 5, 2026. The departure was disclosed in an 8-K filing on June 5, 2026, and Dr. Chaubey's resignation is effective approximately one month after the report date. No reason for the resignation or any compensatory arrangements were disclosed.

• · Dr. Chaubey's resignation is effective July 5, 2026, approximately one month after the filing date.
• · No reason for the resignation was provided in the filing.
• · No successor or interim Chief Medical Officer was announced.

05-06-2026

Albemarle Corporation announced the retirement of Donald J. LaBauve Jr., former Chief Accounting Officer, effective June 1, 2026. Neal R. Sheorey, Executive Vice President and CFO, will serve as interim Principal Accounting Officer starting June 2, 2026, until a permanent replacement is appointed. No new compensatory arrangements or related-party transactions were disclosed in connection with this change.

• · The retirement of Mr. LaBauve was previously reported.
• · Mr. Sheorey's biographical details are incorporated by reference from the company's definitive proxy statement filed March 24, 2026.
• · No family relationships exist between Mr. Sheorey and any other director or executive officer.
• · No transactions involving Mr. Sheorey require disclosure under Item 404(a) of Regulation S-K.

05-06-2026

LCI Industries announced the retirement of CEO Jason Lippert after 32 years and the appointment of independent director Johnny Sirpilla as interim CEO. Additionally, Virginia Henkels was named Chair of the Board, succeeding Tracy Graham, who stepped down. The Board will conduct a comprehensive search for a permanent CEO, considering both internal and external candidates.

• · Jason Lippert will serve in an advisory capacity for one year to support the transition.
• · Johnny Sirpilla has been an LCI Industries Board member since 2019.
• · Virginia Henkels has been a Board member since 2017.
• · Tracy Graham stepped down after 10 years of service to dedicate time to his core business.
• · The Board expressed confidence in the existing management team to maintain operations during the transition.

05-06-2026

Granite Point Mortgage Trust Inc. (GPMT-PA) filed an 8-K on June 5, 2026, reporting that its Board adopted a revised Director Compensation Policy on June 4, 2026, which splits the prior $100,000 RSU award for independent directors equally into a $50,000 RSU award and a $50,000 long-term cash award to limit equity dilution. The company also held its 2026 Annual Meeting on June 4, 2026, where all seven director nominees were elected, the advisory vote on executive compensation was approved (17,500,001 for, 2,152,885 against), and Ernst & Young LLP was ratified as the independent auditor for fiscal 2026 (33,290,665 for, 395,844 against).

• · The revised Policy splits the prior $100,000 RSU award for independent directors into a $50,000 RSU award and a $50,000 long-term cash award, both with one-year vesting.
• · The Chair receives an $80,000 RSU award and an $80,000 long-term cash award under the revised Policy.
• · All seven director nominees were elected with broker non-votes of 13,057,901 for each nominee.
• · The advisory vote on executive compensation passed with 17,500,001 for, 2,152,885 against, and 1,412,480 abstentions.
• · Ratification of Ernst & Young LLP as auditor received 33,290,665 for, 395,844 against, and 436,758 abstentions.

05-06-2026

Trio Petroleum Corp increased CEO Robin Ross's base salary from $400,000 to $600,000 per year, granted a one-time award of 1,500,000 shares, and increased his maximum bonus to 200% of salary. CFO Gregory Overholtzer received a one-time award of 200,000 shares. The changes were approved by the Compensation Committee on June 2, 2026, effective June 1, 2026.

• · The salary increase and stock awards were approved by the Compensation Committee on June 2, 2026.
• · The CEO's cash bonus of $300,000 is payable on August 1, 2026, or at such other time as directed by Mr. Ross.
• · The company intends to enter into Award Agreements with both executives promptly after the filing of this 8-K.

05-06-2026

Lakeside Holding Ltd (LSH) announced the resignation of Co-CEO Henry Liu, effective June 2, 2026, with no disagreement with the company cited. Following his departure, Yang Li becomes the sole CEO. The filing does not include any financial data or period-over-period comparisons.

• · Henry Liu's resignation was not due to any disagreement with the company's operations, policies, or practices.
• · Yang Li now serves as the sole Chief Executive Officer.
• · The resignation was effective June 2, 2026, and the filing was made on June 5, 2026.

05-06-2026

Rocket Lab Corporation appointed Agostino Ricupati as Vice President, Corporate Controller and Chief Accounting Officer, effective June 3, 2026, succeeding Adam C. Spice who remains CFO. Mr. Ricupati brings over two decades of finance leadership from public companies including Cooper Companies and Intel. His compensation includes a $350,000 base salary, a $50,000 sign-on bonus, and a $3,000,000 RSU award vesting over four years.

• · Mr. Ricupati is a licensed CPA with over 20 years of experience at publicly traded multinational companies.
• · No family relationships or material transactions exist between Mr. Ricupati and the company's directors or officers.
• · Mr. Ricupati will participate in the company's standard indemnification agreement and Executive Severance Plan.
• · The RSU award vests over four years, with the number of shares determined per company standard practice.

05-06-2026

Purple Innovation, Inc. announced the resignation of Chief Operating Officer Eric Haynor, effective June 5, 2026. The resignation is not due to any disagreement with the company regarding its operations, policies, or practices. A replacement has not yet been appointed.

• · Eric Haynor's resignation as COO is effective June 5, 2026.
• · The resignation is not related to any disagreement with the company's operations, policies, or practices.
• · No successor has been appointed as of the filing date.

05-06-2026

Lucid Group held its 2026 Annual Meeting on June 4, 2026, where stockholders approved all four proposals, including the election of nine directors, ratification of KPMG as auditor, advisory approval of executive compensation, and the amendment and restatement of the 2021 Stock Incentive Plan. The Plan increases the number of shares available for issuance by 23,500,000 shares. All director nominees received strong support, with votes for ranging from ~255.2M to ~260.4M, while the advisory vote on executive compensation saw ~255.95M for and ~5.41M against, indicating broad but not unanimous approval.

• · The record date for the Annual Meeting was April 6, 2026.
• · Ratification of KPMG as independent auditor received 300,971,935 votes for, 1,906,185 against, and 1,157,127 abstentions.
• · Advisory vote on executive compensation: 255,952,612 for, 5,411,173 against, 251,876 abstentions.
• · Approval of the Stock Incentive Plan amendment: 253,997,107 for, 7,435,259 against, 183,295 abstentions.
• · Broker non-votes were 42,419,586 for all director elections and proposals except the auditor ratification (which had no broker non-votes).

05-06-2026

Claros Mortgage Trust, Inc. held its 2026 annual meeting on June 3, 2026, where stockholders approved an amendment to the 2016 Incentive Award Plan, increasing the share reserve by 6.5 million shares to 14,781,594 shares and raising the ISO limit to 7.5 million shares. All nine director nominees were elected, and the appointment of PricewaterhouseCoopers LLP as auditor was ratified. However, the advisory vote on executive compensation (Say-on-Pay) received only 66.3% support, with 33.6% against, indicating significant shareholder dissent.

• · Derrick D. Cephas received the lowest support among director nominees with 81,678,525 votes for and 24,347,362 withheld (23.0% withheld).
• · Pamela Liebman and W. Edward Walter III each had over 19.8 million votes withheld (18.8% withheld).
• · The Say-on-Pay proposal had 35,691,548 votes against, representing 33.6% of votes cast.
• · The Plan Amendment (Proposal 4) passed with 70,802,303 for and 35,056,699 against (33.1% against).
• · The ISO grant period was extended through April 20, 2036.

05-06-2026

Lifecore Biomedical held its 2026 Annual Meeting on June 4, 2026, where stockholders approved all four proposals, including the election of nine directors, ratification of KPMG LLP as auditor, approval of executive compensation (non-binding), and the new 2026 Stock Incentive Plan. The 2026 Plan, effective October 16, 2026, authorizes up to 2,500,000 new shares plus shares forfeited under the prior 2019 Plan. All director nominees received majority support, though Katrina L. Houde and Joshua E. Schechter faced notable opposition with over 3.3 million and 2.7 million votes withheld, respectively.

• · The 2026 Stock Incentive Plan was approved with 22,724,492 votes for, 392,825 against, and 13,086 abstentions (broker non-votes: 10,697,326).
• · Ratification of KPMG LLP as independent auditor was approved with 33,760,879 votes for, 63,445 against, and 3,405 abstentions.
• · Advisory approval of executive compensation passed with 22,938,684 votes for, 178,868 against, and 12,851 abstentions (broker non-votes: 10,697,326).
• · Two director nominees (Katrina L. Houde, Joshua E. Schechter) received more than 3.3 million and 2.7 million votes withheld, respectively, indicating notable shareholder dissent.
• · The 2026 Plan becomes effective October 16, 2026, and the 2019 Plan will expire on that date.
• · The record date for the meeting was April 6, 2026.

05-06-2026

OptimizeRx Corp announced the separation of Chief Commercial Officer Theresa Greco, effective June 15, 2026, with a separation agreement providing 12 months of base salary continuation ($380,000/year), a lump-sum cash bonus of $209,000, and COBRA reimbursement. Ms. Greco will serve as an advisor through June 15, 2027, with continued equity vesting and a potential change-in-control bonus. The departure is a planned executive transition, but the associated severance costs and advisory arrangement represent additional near-term expenses.

• · Separation agreement includes a general release of claims and non-compete/non-solicit obligations for 12 months.
• · Ms. Greco's equity grants will continue to vest during the advisory term.
• · A special bonus may be payable upon a change in control during the advisory term per a September 8, 2025 agreement.
• · The separation was previously disclosed in the Q1 2026 10-Q filed on May 11, 2026.

05-06-2026

Dream Finders Homes appointed Clint Szubinski as Chief Operating Officer, effective immediately. The move strengthens the executive team as the company expands across the Southeast, Mid-Atlantic, and Midwest. No financial impact or concurrent financial results were disclosed.

• · Mr. Szubinski previously served as EVP and COO at Meritage Homes, and as President of Meritage's East Region.
• · He will work alongside National President Doug Moran to transition teams and responsibilities.
• · DFH builds in Florida, Texas, Tennessee, North Carolina, South Carolina, Georgia, Colorado, Arizona, and the Washington, D.C. metro area.
• · The company was recognized as the 2025 National Builder of the Year by Builder magazine.

05-06-2026

Grindr Inc. held its 2026 annual meeting on June 2, 2026, where stockholders approved the amendment and restatement of the Grindr Inc. 2022 Equity Incentive Plan. The A&R Plan increases the share reserve by 11,600,000 shares, introduces stockholder approval requirements for repricing of stock options and stock appreciation rights, and mandates that dividends on unvested awards be accumulated and subject to the same vesting conditions as the underlying award.

• · The A&R Plan introduces a requirement for stockholder approval for repricing of outstanding stock options and stock appreciation rights.
• · Dividends or dividend equivalents on unvested awards will be accumulated and not paid until the underlying award vests, and will be forfeited if the award is forfeited.
• · The detailed description of the A&R Plan was included in the definitive proxy statement filed on April 30, 2026.

05-06-2026

New Fortress Energy Inc. announced the resignation of Chief Accounting Officer Michael Lowe, effective July 1, 2026, and the appointment of Frederick Hundt as his successor. Mr. Lowe provided exemplary leadership during the company's complex restructuring, which is nearing completion. The transition appears orderly with the successor already serving as Global Controller since June 2025.

• · Michael Lowe has been with the company since 2019, first as SVP then as CAO.
• · Before joining NFE, Mr. Lowe was a Director in PwC's Capital Markets and Accounting Advisory Services practice (2008-2019).
• · Frederick Hundt previously served as Corporate Controller of GXO Logistics (April 2023 to June 2025) and held finance/accounting leadership roles at Mastercard (2015-2023), including Assistant Corporate Controller.
• · Mr. Hundt spent 11 years in PwC's audit practice, including time in the national office supporting SEC reporting and compliance.
• · Mr. Hundt joined NFE in June 2025 as Global Controller and has already been working to strengthen the accounting organization.

05-06-2026

DeEtte Gray, President of U.S. Operations at CACI International Inc, notified the company of her retirement effective June 30, 2026. She will remain as a Strategic Advisor through December 31, 2026 under a Transition and Separation Agreement that provides a prorated base salary of $763,497, reduced bonus participation, and a significantly reduced long-term equity grant, but no severance or change-in-control benefits. The transition is intended to support an orderly leadership handover.

• · Transition Period runs from July 1, 2026 to December 31, 2026.
• · Ms. Gray will not be eligible for additional long-term incentive awards in 2026.
• · The Transition Agreement does not provide severance or change-in-control benefits.
• · Incentive compensation during the Transition Period is subject to the company's clawback policy.
• · The agreement was approved by the company's Human Resources and Compensation Committee.

05-06-2026

Graham Corporation's Compensation Committee approved Fiscal 2027 long-term incentive awards and cash bonus program for senior executives, granting RSUs and PSUs to named executive officers. The filing also details the retirement of Alan Smith from his VP role effective April 1, 2026, and the grant of RSUs to non-employee directors. No financial results or period-over-period comparisons are included in this filing.

• · PSU vesting is based 50% on three-year average ROIC change and 50% on three-year cumulative revenue growth; no payout if below threshold.
• · RSUs vest one-third annually over three years; PSUs vest on third anniversary.
• · Alan Smith retired as VP and General Manager effective April 1, 2026, and will not participate in Fiscal 2027 LTI or cash bonus programs.
• · Cash bonus performance weightings: Adjusted EBITDA 40%, Bookings 20%, Safety Goals 20%, Personal Goals 20%.
• · Safety goals are based on consolidated total recordable incident rate with a minimum threshold per business unit and Board discretion for catastrophic events.
• · Non-employee directors each received 905 RSUs, valued at $90,000 based on $99.41 closing price.

05-06-2026

At the June 4, 2026 Annual Meeting, Charlie's Holdings stockholders approved a reverse stock split (ratio range 1-for-3 to 1-for-50) to facilitate up-listing to a national exchange, and increased the 2019 Omnibus Equity Incentive Plan by 15 million shares. All five director nominees were elected with overwhelming support. The independent auditor appointment was also ratified.

• · The reverse stock split authorization has a two-year window for implementation at the Board's discretion.
• · The auditor ratification vote received 228,243,644 votes for, with zero broker non-votes.
• · Broker non-votes were 17,908,420 for director elections and the plan amendment, but zero for auditor ratification and reverse split proposals.
• · All director nominees received between 210,390,660 and 210,410,765 votes for; the highest withhold vote was 259,993 (Scot Cohen).
• · The 8-K was signed by Ryan Stump, Chief Operating Officer, on June 5, 2026.

05-06-2026

Indaptus Therapeutics, Inc. announced the resignation of two directors, David E. Lazar and Avraham Ben-Tzvi, effective June 5, 2026, and the resignation of Chief Operating Officer Walt A. Linscott, effective June 1, 2026. Mr. Linscott will continue as a consultant under a consulting agreement. All resignations were not due to any disagreement with the company.

• · Mr. Linscott's resignation as COO was effective June 1, 2026, and he entered into a consulting agreement with the company on the same date.
• · The resignations of Mr. Lazar and Mr. Ben-Tzvi were effective June 5, 2026, and included all committee positions.
• · All resignations were stated to be not due to any disagreement with the company's operations, policies, or practices.

05-06-2026

Jupiter Neurosciences, Inc. appointed Alison Silva as Chief Operating Officer and President, increasing her base salary to $340,200 from $315,000, and granted her options for 600,000 shares. The company also awarded discretionary bonus options in lieu of cash to five executives totaling approximately 2,101,726 shares, and granted 100,000 options to each independent non-employee director. All option grants vest quarterly over three years starting September 2, 2026.

• · Amendment No. 3 to employment agreement with Alison Silva dated June 5, 2026.
• · All option grants vest quarterly over three years starting September 2, 2026.
• · Discretionary bonus options were granted in lieu of cash.
• · The company is an emerging growth company and has not elected to use the extended transition period for new accounting standards.

05-06-2026

Aditxt, Inc. announced the immediate resignation of Christopher J. Porcelli as General Counsel, Chief People Officer and Corporate Secretary, and the resignation of Brian Brady as non-executive Chairman and Board member, both effective June 2, 2026. Brady's departure was not due to any disagreement with the company. The departures remove two senior leaders, including the head of legal and the audit committee chair, creating governance gaps.

• · Brian Brady's resignation was not the result of any disagreement with the company on any matter relating to the company's operations, policies, or practices.
• · Brady served as Chair of the Audit Committee and was a member of the Compensation Committee and the Nominating and Corporate Governance Committee.
• · The resignations were effective immediately on June 2, 2026.
• · The filing does not disclose any replacements or interim appointments for the vacated positions.

05-06-2026

NovoCure Ltd held its annual general meeting on June 3, 2026, where shareholders elected 11 directors, ratified the appointment of Kost Forer Gabbay & Kasierer (EY) as auditor for FY2026, approved executive compensation on a non-binding advisory basis, and approved the Amended and Restated 2024 Omnibus Incentive Plan. The meeting saw strong shareholder turnout of 81.01% of eligible shares. However, the Omnibus Incentive Plan was approved by a very narrow margin (50.3% for vs. 49.7% against), indicating significant shareholder dissent.

• · The Amended and Restated 2024 Omnibus Incentive Plan passed with only 41,680,622 votes for versus 41,161,139 against (excluding 10,874,130 broker non-votes), a razor-thin margin of 519,483 votes.
• · Executive compensation (say-on-pay) received 75,392,168 for, 7,422,876 against, and 137,556 abstentions (excluding broker non-votes), representing approximately 91.0% approval of votes cast.
• · Auditor ratification passed overwhelmingly with 91,436,910 for, 2,337,255 against, and 52,565 abstentions.
• · All 11 director nominees received substantial support, with Frank Leonard receiving the highest 'for' votes (82,547,254) and Kinyip Gabriel Leung the lowest (79,455,754).
• · The meeting had 10,874,130 broker non-votes on all director elections and the non-binding advisory vote on executive compensation.

05-06-2026

Carlyle Group Inc. held its 2026 Annual Meeting on June 3, 2026, where shareholders approved the Amended and Restated 2012 Equity Incentive Plan and ratified Ernst & Young LLP as independent auditor. All thirteen director nominees were elected, and the say-on-pay proposal passed, though with significant opposition on both the equity plan (49.4 million against) and say-on-pay (55.0 million against).

• · Harvey M. Schwartz received the highest support with 99.2% of votes cast, while Anthony Welters had the lowest support at 95.1%.
• · The equity incentive plan approval received 252,707,398 votes in favor but 49,426,621 against, representing 16.4% opposition among votes cast.
• · Say-on-pay had 246,902,606 votes in favor and 54,984,239 against, representing 18.2% opposition among votes cast, which may signal shareholder concerns on executive compensation.
• · Ernst & Young LLP was ratified as independent auditor with 325,337,355 votes for and only 7,384,983 against, receiving 97.8% support from votes cast.

05-06-2026

Core Molding Technologies appointed President & CEO Eric Palomaki to the Board on June 5, 2026, filling the vacancy left by David L. Duvall's resignation. Concurrently, the company entered into an Amended and Restated Employment Agreement with Palomaki effective June 1, 2026, providing a base salary of $525,000, an initial restricted stock grant of 20,000 shares vesting over three years, and annual STIP and LTIP targets of 100% and 200% of base salary, respectively. The agreement includes enhanced severance of four times base salary for termination without cause or for good reason, but no additional compensation for board service.

• · David L. Duvall resigned from the Board effective June 1, 2026.
• · Eric Palomaki has not been assigned to any Board committee; assignment will occur later.
• · Palomaki will not receive additional compensation for board service.
• · The Amended Employment Agreement has no fixed term and remains in effect until terminated.
• · Upon termination without cause, for good reason, or qualified retirement, Palomaki receives 4× base salary ($2.1M) but forfeits unvested equity.
• · Upon death or disability, Palomaki receives pro-rata STIP, accelerated equity vesting, and cash equal to 20-trading-day average closing price.
• · Restrictive covenants include a two-year non-solicitation of employees, confidentiality, and non-disparagement.

05-06-2026

On June 5, 2026, Auburn National Bancorporation's Compensation Committee granted 4,475 Restricted Stock Units (RSUs) to three named executive officers: David A. Hedges (2,078 RSUs), W. James Walker IV (1,207), and Robert L. Smith (1,190) under the 2024 Equity and Incentive Compensation Plan. The RSUs vest one-third annually over three years (2027–2029) and include dividend equivalents. No financial results or performance figures were disclosed, but the grant reflects ongoing executive compensation alignment.

• · RSUs carry no ownership rights until vested.
• · Dividend equivalents are issued as additional RSUs calculated using the dividend amount divided by the closing stock price.
• · Vesting accelerates 100% upon death or disability; pro-rata vesting on retirement; pro-rata on termination without cause; full vesting upon change in control if RSUs are not assumed.
• · Post-employment restrictive covenants include two-year confidentiality, one-year non-solicitation of employees, and one-year non-solicitation of customers.
• · RSUs cannot be pledged, assigned, or transferred.
• · The award agreement is subject to the company's insider trading policy.

05-06-2026

Thomas C. Chubb, III resigned from the Board of Flowers Foods, Inc. effective June 4, 2026, due to competing professional demands as chairman, president and CEO of Oxford Industries, Inc. His departure was not due to any dispute with the Board or Company. The Board thanked him for six years of service, including as independent presiding director and chair of the Nominating/Corporate Governance Committee.

• · Resignation was effective immediately on June 4, 2026.
• · Mr. Chubb served as independent presiding director and chair of the Nominating/Corporate Governance Committee.
• · The filing was signed by CFO D. Anthony Scaglione on June 5, 2026.

05-06-2026

On June 5, 2026, Petros Pharmaceuticals, Inc. granted an aggregate of 7,000,000 restricted shares to four directors and officers, with 50% vesting immediately and the remaining 50% vesting in six months. The largest award went to Chairman Joshua Silverman (4,375,000 shares), while President Fady Boctor and director Wayne Walker each received 375,000 shares. The grants were made outside the company's existing equity incentive plan.

• · The RSA Awards were issued outside the company's Amended and Restated 2020 Omnibus Incentive Compensation Plan.
• · Vesting of the remaining 50% is contingent on the recipient providing services to the company on the six-month anniversary of the Grant Date.
• · The grants were approved by the Board of Directors on June 5, 2026.

05-06-2026

At its 2026 annual meeting held on June 3, 2026, GoDaddy Inc. stockholders approved an amended and restated 2024 omnibus incentive plan, increasing authorized shares by 3,116,000, and elected all nine director nominees to serve until the 2027 annual meeting. Advisory approval of named executive officer compensation received strong support with over 92% of votes cast in favor (101,962,417 for vs. 8,404,346 against), though roughly 7.4 million broker non-votes were recorded on most proposals.

• · The amended plan was previously approved by the Board and details were described in the April 24, 2026 proxy statement, Appendix B.
• · Ratification of Ernst & Young LLP as independent auditor for year ending December 31, 2026 received 111,168,218 for, 6,796,303 against, and 78,461 abstain.
• · Broker non-votes on director election, advisory compensation vote, and incentive plan vote were each 7,411,243 (except the auditor ratification which had no broker non-votes).
• · Director Leah Sweet received the highest number of 'against' votes (3,168,349) among all nominees.
• · The CEO & CFO compensation was approved on a non-binding advisory basis with 101,962,417 for, 8,404,346 against, and 264,976 abstain.

05-06-2026

CareCloud, Inc. filed an 8-K disclosing the adoption of a new 2026 Equity Incentive Plan by the Board on March 24, 2026, which was approved by shareholders. The plan authorizes up to 1,000,000 shares of common stock for issuance under various award types, including stock options, restricted stock, and performance awards. The filing also covers director/officer departure/election matters (Items 5.02 and 5.07), though no specific personnel changes are detailed in the exhibit.

• · The plan was adopted by the Board on March 24, 2026, and filed with the SEC on June 5, 2026.
• · Award types include Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Unit Awards, Performance Stock Awards, Performance Cash-Settled Awards, and Other Stock Awards.
• · Eligible recipients are Employees, Directors, and Consultants.
• · The plan includes a limit on awards to Non-Employee Directors: total value of awards plus cash fees in a fiscal year cannot exceed a specified number (placeholder $[NUMBER] in the filing).
• · The plan prohibits repricing of Options or SARs without shareholder approval within the prior 12 months, except for nominal cash cancellations not treated as repricing under GAAP.
• · The plan allows for a reverse stock split adjustment to the share reserve if implemented contemporaneously with adoption.
• · The plan includes provisions for compliance with Section 409A of the Code and Rule 16b-3.

05-06-2026

Red Violet, Inc. held its 2026 Annual Meeting on June 3, 2026, where all five director nominees were elected, Grant Thornton, LLP was ratified as the independent auditor for 2026, and the say-on-pay proposal was approved on an advisory basis. However, director nominee Steven Rubin received a significant number of withheld votes (5,343,299), representing over 55% of votes cast, indicating notable shareholder dissent.

• · Steven Rubin received 4,346,340 FOR votes and 5,343,299 WITHHELD votes, the highest withheld count among all nominees.
• · Derek Dubner received 8,474,133 FOR and 1,215,506 WITHHELD votes.
• · William Livek received 9,401,190 FOR and 288,449 WITHHELD votes.
• · Lisa Stanton received 9,421,726 FOR and 267,913 WITHHELD votes.
• · Greg Strakosch received 9,530,425 FOR and 159,214 WITHHELD votes.
• · Ratification of Grant Thornton received 12,083,156 FOR, 9,602 AGAINST, and 1,906 ABSTAIN, with no broker non-votes.
• · Say-on-pay received 8,925,718 FOR, 238,311 AGAINST, and 525,610 ABSTAIN, with 2,405,025 broker non-votes.

05-06-2026

On June 4, 2026, Jordan Krugman notified the Invesco CurrencyShares Australian Dollar Trust of his resignation from all positions at the Sponsor, Invesco Specialized Products, LLC, and its affiliates, including his role on the Board of Managers, effective August 3, 2026. The Sponsor is currently considering a replacement. No financial figures or performance metrics were disclosed in this filing.

• · Resignation effective date: August 3, 2026
• · Filing date: June 5, 2026
• · Trust's sponsor is Invesco Specialized Products, LLC

05-06-2026

Charlotte's Web Holdings announced that co-founder Jared Stanley has stepped down from its Board of Directors effective June 3, 2026, to focus full-time on his role as CEO of DeFloria, a clinical-stage botanical pharmaceutical company co-founded by Charlotte's Web. The Board supports the transition, and Mr. Stanley will remain available for advisory support. The move underscores Charlotte's Web's strategic alignment with DeFloria's FDA Phase 2 development of AJA001 for autism-related irritability, while the core wellness business continues independently.

• · DeFloria was formed in 2023 by Charlotte's Web and AJNA BioSciences PBC, with a subsidiary of British American Tobacco p.l.c. as lead investor.
• · AJA001 is being developed for irritability associated with autism spectrum disorder via the FDA's Botanical Drug Pathway.
• · Jared Stanley will continue his role on ONE HEMP, the national industry coalition co-founded by Charlotte's Web.
• · The 2025 U.S. executive actions are expected to support cannabinoid drug development by expanding research access and reducing barriers to pharmaceutical partnerships.

05-06-2026

Applied Optoelectronics, Inc. (AAOI) held its 2026 Annual Meeting on June 4, 2026, where shareholders approved the new 2026 Equity Incentive Plan, authorizing an additional 2,500,000 shares, and ratified the appointment of PricewaterhouseCoopers as the independent auditor for fiscal year 2026. Two Class I directors were elected, and advisory say-on-pay, charter amendment, and meeting adjournment proposals also passed. The shareholder turnout was 64.18% of eligible shares (51,375,083 votes). However, the approval of the 2026 Equity Incentive Plan received the lowest support among all proposals, with 34,862,167 for and 3,780,336 against (about 10.8% against), indicating notable shareholder dissent.

• · The 2026 Equity Incentive Plan replaces the Amended and Restated 2021 and 2013 Equity Incentive Plans; no new awards will be granted under the prior plans.
• · The 2026 Plan also includes shares previously reserved but not issued under the 2021 Plan, as well as shares from outstanding 2021 Plan awards that lapse or are forfeited.
• · Directors Che-Wei Lin and Robert Flanagan were elected, with Lin receiving 3,227,489 withheld votes (about 8.6% of votes cast) vs. Flanagan's 924,704 withheld (2.4%).
• · Advisory say-on-pay passed with 38,001,385 for, but 672,239 against (1.8% of votes cast excluding broker non-votes).
• · The charter amendment to clarify voting standard for future amendments passed with 38,486,404 for and only 305,242 against.
• · The proposal to adjourn the meeting passed with 47,987,329 for vs. 3,100,990 against.
• · The report was signed by David C. Kuo, Senior Vice President and Chief Legal Officer.

05-06-2026

On June 1, 2026, RYVYL Inc. (formerly RTB Digital, Inc.) announced the departure of co-founder David Bailey from the board of directors to focus on his role as CEO of Nakamoto, Inc. (NASDAQ: NAKA). The departure is amicable and not due to any disagreement. No financial impact is disclosed.

• · David Bailey co-founded the recently acquired business and served as a founding investor and board member.
• · He previously served on a public-company board with founder James Heckman.
• · The departure is effective June 1, 2026, and is not due to any disagreement.

05-06-2026

CaliberCos Inc. announced that CFO Jade Leung will step down after an 11-year tenure, with Michael Rosales appointed as Acting CFO effective June 14, 2026. The company reaffirmed its full-year 2026 guidance and stated the transition does not affect strategy or financial outlook. A search for a permanent CFO has commenced, seeking a leader with expertise in capital formation, real estate finance, and digital asset tokenization.

• · Jade Leung's departure is not due to any disagreement with the company on operations, accounting policies, or financial reporting.
• · Michael Rosales joined Caliber in October 2020 and most recently served as Senior Vice President of Accounting, Financial Reporting & Tax since April 2025.
• · The Board intends to consider both internal and external candidates for the permanent CFO role.
• · Caliber integrated digital asset infrastructure in 2025 by investing in LINK, the token underlying Chainlink.

05-06-2026

On June 4, 2026, Jordan Krugman notified Invesco Galaxy Solana ETF of his resignation from all positions at the Sponsor (Invesco Capital Management LLC) and its affiliates, including his role on the Board of Managers, effective August 3, 2026. The Sponsor is currently considering a replacement. No financial impact or performance data is disclosed in this filing.

• · Resignation effective date: August 3, 2026.
• · The registrant is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
• · The filing does not disclose any financial metrics, performance data, or material changes to the fund's operations or strategy.

05-06-2026

Block, Inc. announced the departure of Engineering Lead Arnaud Weber on June 5, 2026. Following his departure, the engineering organization will report directly to Block Head Jack Dorsey. No financial figures or performance metrics were disclosed in this filing.

• · The engineering organization will report directly to Jack Dorsey following Mr. Weber's departure.
• · The departure was effective June 5, 2026.

05-06-2026

MBX Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders elected Patrick J. Heron and Edward T. Mathers as Class II directors for three-year terms and ratified Ernst & Young LLP as independent auditor for fiscal 2026. The meeting had 47,570,485 shares outstanding as of the record date.

• · Patrick J. Heron received 35,007,623 votes for, 4,579,129 withheld, and 4,130,833 broker non-votes.
• · Edward T. Mathers received 31,983,223 votes for, 7,603,529 withheld, and 4,130,833 broker non-votes.
• · Ratification of Ernst & Young LLP received 43,713,693 votes for, 1,946 against, and 1,946 abstentions.

05-06-2026

Upwork Inc. held its 2026 annual meeting on June 4, 2026, where stockholders elected three Class II directors (Claire Bramley, David Lissy, and Gary Steele) and approved all other proposals, including ratification of PwC as auditor and an advisory vote on executive compensation. However, director Gary Steele received significant opposition with 17.1 million votes against (17.9% of votes cast), and the advisory vote on executive compensation also saw notable dissent with 26.8 million votes against (28.0% of votes cast), indicating mixed shareholder sentiment.

• · Claire Bramley and David Lissy were appointed to the audit, risk and compliance committee effective immediately after the annual meeting.
• · The board eliminated the Class III directorship held by Anilu Vazquez-Ubarri and reassigned it as a Class II directorship.
• · Broker non-votes totaled 9,894,401 shares on director elections and the executive compensation advisory vote.
• · The next advisory vote on the frequency of future advisory votes on executive compensation is expected at the 2032 annual meeting.
• · The company's standard form of indemnity agreement was entered into by both new directors.

05-06-2026

AbCellera Biologics Inc. announced the appointment of Dr. Victor Sandor to its Board of Directors as an independent director, effective June 5, 2026. Dr. Sandor brings extensive experience in oncology drug development and approvals, including leadership roles at Array BioPharma, Incyte, Biogen, and AstraZeneca. The filing contains no financial data or period-over-period comparisons.

• · Dr. Sandor currently serves on the boards of ADC Therapeutics SA, Kymera Therapeutics Inc., and Prelude Therapeutics Incorporated.
• · He previously served on the board of Merus N.V. prior to its acquisition by Genmab A/S in 2025.
• · Dr. Sandor received his M.D.C.M. from McGill University and completed a Fellowship in Medical Oncology at the National Institutes of Health.

05-06-2026

Grace Therapeutics, Inc. announced the departure of Carrie D'Andrea as Vice President of Clinical Operations, effective June 5, 2026. She will transition to a twelve-month consulting role at $250 per hour, with continued vesting of stock options during the consulting term. The separation is subject to a release of claims and compliance with non-competition and non-solicitation covenants.

• · The separation was approved on June 1, 2026, and effective June 5, 2026.
• · Ms. D'Andrea's stock options will continue to vest during the consulting term under the Grace Therapeutics 2024 Equity Incentive Plan and the Acasti Pharma Inc. Stock Option Plan.
• · She has 90 days after the consulting agreement ends to exercise any vested stock options.
• · The separation agreement is conditioned on a release of claims and compliance with continuing obligations including non-competition and non-solicitation covenants.